Abbott Laboratories

Abbott Laboratories is a U.S.-based healthcare company that discovers, develops, manufactures, and sells a diversified portfolio spanning medical devices, diagnostic testing systems, nutrition products, and branded generic pharmaceuticals. Its operating model combines regulated manufacturing and R&D with large-scale commercial distribution to hospitals, labs, pharmacies, and consumer retail channels across many countries. Abbott organizes its business into four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In November 2025, Abbott agreed to acquire Exact Sciences Corporation, a move intended to add cancer diagnostics capabilities pending shareholder and regulatory approvals.

21,4 %

56,4 %

14,7 %

+5,7 %

1.58

1.18

— Abbott Laboratories
%
Medical Devices48% Implantable and interventional devices across cardiovascular and rhythm management and other device franchises.
Diagnostic Products20% Core lab immunoassay/clinical chemistry systems (e.g., Alinity) and rapid diagnostics platforms and tests.
Nutritional Products19% Pediatric and adult nutrition products sold through healthcare and consumer retail channels.
Established Pharmaceutical Products13% Branded generic pharmaceuticals marketed primarily outside the U.S., including select biosimilars.

Abbott sells to a mix of institutional healthcare customers and consumer channels depending on the segment...

  • Hospitals and procedure centersprimary

    Purchase medical devices (e.g., rhythm management implants) driven by procedure volumes, physician adoption, and reimbursement.

  • Clinical laboratories and health systemsprimary

    Buy diagnostics instruments (Alinity), assays, and rapid tests to run routine and acute testing with contracted pricing and service support.

  • Retail and e-commerce consumerssecondary

    Buy nutrition products for daily health management, with demand shaped by brand trust and product innovation aligned to preferences.

  • Wholesalers, distributors, and pharmacies (ex-U.S.)secondary

    Purchase established pharmaceutical products (branded generics) for broad therapeutic portfolios in emerging markets.

  • Government agencies and public procurement bodiesemerging

    Buy pharmaceuticals and diagnostics through tenders and reimbursement systems, influencing volumes and net pricing via controls and rebates.

Abbott operates globally with manufacturing, sourcing, and sales across the U.S. and international markets, and its...

  • •International markets generated ~61% of 2025 net sales, driving FX exposure
  • •U.S. remains a major market for devices, diagnostics, and nutrition demand
  • •Emerging markets are central for Established Pharmaceuticals distribution
  • •Some currencies face exchange controls, affecting cash movement and pricing
  • •China procurement programs can pressure diagnostics volumes and pricing
  • •Russia/Ukraine exposure is ~2% of revenues and net assets (per 10-K)

Abbott’s near-term strategy emphasizes product-driven growth within each segment rather than reliance on a single...

01
Accelerate diagnostics growth via Alinity and menu expansionmedium-term

Instrument placements and broader menus increase recurring reagent pull-through and customer switching costs.

02
Scale growth in medical devices through new product rampsmedium-term

Newer platforms can expand addressable markets and offset declines in mature device categories.

03
Portfolio expansion in emerging markets and biosimilarslong-term

Branded generics and biosimilars can compound growth where healthcare access is expanding and pricing dynamics differ from the U.S.

04
Add cancer diagnostics capabilities through M&Ashort-term

Cancer screening/diagnostics expands Abbott’s diagnostics addressable market and complements existing testing platforms.

Abbott’s performance depends on a large, complex global supply chain; disruptions (from pandemics, inflation, labor...

high

Global supply chain disruption

A large, complex supply chain is exposed to shortages, inflation, and logistics constraints that can affect cost and availability.

Scope
Global manufacturing and sourcing network
Materiality
high
high

Foreign exchange and exchange controls

A significant portion of revenues and costs are in non-USD currencies; translation and controls can affect reported results and cash flows.

Scope
~61% of 2025 net sales outside the U.S.
Materiality
high
high

Regulatory compliance and product oversight

Products and labs are subject to extensive regulation, inspections, and post-market requirements that can lead to delays or remediation.

Scope
FDA and global regulators; lab certifications and licensure
Materiality
high
high

Cybersecurity incident affecting systems or protected data

Dependence on sophisticated information systems and third parties increases risk of operational disruption and data exposure.

Scope
Enterprise IT, connected devices/labs, third-party providers
Materiality
medium
medium

M&A and integration risk (including pending Exact Sciences deal)

Acquisitions can create execution risk, unexpected costs, and profitability dilution if synergies or growth do not materialize.

Scope
Business development and integration activities
Materiality
medium
Goodwill and intangible asset impairment/valuation
Potential impairment charges and amortization affecting operating income
Derivatives and hedging for foreign currency exposure
Volatility in reported results and cash flow presentation
Revenue recognition and net sales adjustments
Timing and level of reported net sales and receivables

AbbVie Inc.

ABBV · Pharmaceutical Preparations

Avantor, Inc.

AVTR · Laboratory Analytical Instruments

QUEST DIAGNOSTICS INC

DGX · Services-Medical Laboratories

AbCellera Biologics Inc.

ABCL · Pharmaceutical Preparations

ATI INC

ATI · Steel Pipe & Tubes

HOLOGIC INC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus

: 11/08/2026